摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,3-dimethylbutyl carbamate | 1364663-99-9

中文名称
——
中文别名
——
英文名称
2,3-dimethylbutyl carbamate
英文别名
——
2,3-dimethylbutyl carbamate化学式
CAS
1364663-99-9
化学式
C7H15NO2
mdl
——
分子量
145.202
InChiKey
SGGABIGYBNIADX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    10
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.86
  • 拓扑面积:
    52.3
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    2,3-二甲基丁酸 在 lithium aluminium tetrahydride 、 三氟乙酸 作用下, 以 二氯甲烷 为溶剂, 反应 29.0h, 生成 2,3-dimethylbutyl carbamate
    参考文献:
    名称:
    新型支链烷基氨基甲酸酯的合成及其抗惊厥活性的评价
    摘要:
    合成了一类新型的19种氨基甲酸酯,并在大鼠最大电击(MES)和皮下甲硝唑(scMet)癫痫发作测试和毛果芸香碱引起的癫痫持续状态(SE)模型中比较了它们的抗惊厥活性。尽管所述烷基氨基甲酸酯紧密的结构特征,仅化合物34,38,和40都处于活动状态的MES试验。癫痫发作后30分钟,类似物2-乙基-3-甲基-丁基-氨基甲酸酯(34)和2-乙基-3-甲基-戊基-氨基甲酸酯(38)也表现出有效的活性。将同源氨基甲酸酯的脂族侧链从7延伸到8(34到35)和同源物38和43中的8至9个碳降低了毛果芸豆SE模型中的活性,从ED 50 = 81 mg / kg(34)降至94 mg / kg(35)和96 mg / kg(38)。分别达到114 mg / kg(43)。最有效的氨基甲酸酯,苯基-乙基-氨基甲酸酯(47)(MES ED 50 = 16 mg / kg)在其结构中包含一个芳香族部分。化合物34,
    DOI:
    10.1021/jm201751x
点击查看最新优质反应信息

文献信息

  • [EN] FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF<br/>[FR] DERIVES DE LA PYRIMIDIN-4(3H)-ONE A CYCLES FUSIONNES, SPN PROCEDE DE PREPARATION ET SES UTILISATIONS
    申请人:SANKYO CO
    公开号:WO2003106435A1
    公开(公告)日:2003-12-24
    AbstractNovel compounds of the following formula (I) and pharmacologically acceptable salt and esters thereof can modulate LXR function and as a result show excellent anti-arteriosclerotic and anti-inflammatory activity:wherein:A represents aryl or heteroaryl;R1, R2 and R3 are the same or different and each represents hydrogen, hydroxyl, nitro, cyano, amino, halogen, carboxy, carbamoyl, mercapto, alkyl, haloalkyl, alkylcarbonyloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino, alkylcarbonylamino, N-(alkylcarbonyl)-N-(alkyl)amino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N-(alkyl)amino, alkylsulfonylamino, N-(alkylsulfonyl)-N-(alkyl)amino, haloalkylsulfonylamino, N-(haloalkylsulfonyl)-N-(alkyl)amino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group, or R1 and R2 together are alkylenedioxy;R4 and R5 are the same or different and each represents hydrogen, hydroxyl, amino, halogen, mercapto, alkyl, haloalkyl, alkoxy, alkoxycarbonyl or alkylthio;X represents hydrogen, hydroxyl, halogen, alkoxy or haloalkoxy; andY represents an optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, cycloalkylalkyl, heterocyclylalkyl or aralkyl group.
    新化合物具有以下式(I)的结构,其药学上可接受的盐和酯可以调节LXR功能,从而表现出优秀的抗动脉粥样硬化和抗炎活性:其中:A代表芳基或杂环芳基;R1、R2和R3相同或不同,每个代表氢、羟基、硝基、氰基、氨基、卤素、羧基、氨基甲酰基、巯基、烷基、卤代烷基、烷基羰氧基、烷氧基、烷硫基、烷磺基、烷基氨基、二烷基氨基、烷基羰基氨基、N-(烷基羰基)-N-(烷基)氨基、烷氧羰基氨基、N-(烷氧羰基)-N-(烷基)氨基、烷磺酰氨基、N-(烷磺酰基)-N-(烷基)氨基、卤代烷基磺酰氨基、N-(卤代烷基磺酰基)-N-(烷基)氨基、烷基羰基、烷氧羰基、烷基氨基羰基或二烷基氨基羰基,或R1和R2一起是亚烷二氧基;R4和R5相同或不同,每个代表氢、羟基、氨基、卤素、巯基、烷基、卤代烷基、烷氧基、烷氧羰基或烷硫基;X代表氢、羟基、卤素、烷氧基或卤代烷氧基;Y代表可选择取代的烷基、环烷基、杂环烷基、芳基、环烷基烷基、杂环烷基烷基或芳基烷基。
  • PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT
    申请人:Ashikawa Masanori
    公开号:US20120004197A1
    公开(公告)日:2012-01-05
    Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of EPO and/or an activity of enhancing the production of hemoglobin. Specifically disclosed is and EPO production enhancer and/or a hemoglobin production enhancer comprising a 1-acyl-4-(substituted oxy, substituted amino, or substituted thio)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by general formula (1) [wherein R 1 , R 2 , R 2′ , R 3 and R 3′ independently represent a hydrogen atom, a C 1-6 alkyl group, or the like; R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 independently represent a hydrogen atom, a halogen atom, a C 1-6 alkyl group, or the like; A represents N—R 11 , a sulfur atom, or an oxygen atom; R 11 represents a hydrogen atom, a C 1-6 alkyl group, or the like; B represents a C 6-14 aryl group, or a 5- to 10-membered heterocyclic group; and n represents an integer of 0 or 1], a salt of the tetrahydroquinoline compound, or a solvate of the tetrahydroquinoline compound or the salt.
    揭示了一种具有低分子量的化合物,具有增强EPO产生和/或增强血红蛋白产生活性的化合物。具体揭示了一种EPO产生增强剂和/或血红蛋白产生增强剂,包括1-酰基-4-(取代氧基、取代氨基或取代硫基)-1,2,3,4-四氢喹啉衍生物,更具体地说是由通式(1)表示的四氢喹啉化合物【其中R1、R2、R2'、R3和R3'独立地表示氢原子、C1-6烷基或类似物;R4、R5、R6、R7、R8、R9和R10独立地表示氢原子、卤素原子、C1-6烷基或类似物;A表示N—R11、硫原子或氧原子;R11表示氢原子、C1-6烷基或类似物;B表示C6-14芳基或5-至10-成员杂环基;n表示0或1的整数】,四氢喹啉化合物的盐,或四氢喹啉化合物或其盐的溶剂化合物。
  • PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA, COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT
    申请人:Kowa Company, Ltd.
    公开号:EP2199283A1
    公开(公告)日:2010-06-23
    Disclosed is a low-molecular-weight compound having an EPO production-promoting activity and/or a hemoglobin expression-enhancing activity. Specifically disclosed is an EPO production promoter and/or a hemoglobin expression enhancer comprising a 1-acyl-4-(phenoxy, benzyloxy or phenylamino)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by the general formula (1); [wherein R1, R2, R2', R3 and R3' independently represent a hydrogen atom, a C1-6 alkyl group, or the like; R4, R5, R6, R7, R8, R9 and R10 independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, or the like; A represents N-R11 or an oxygen atom; R11 represents a hydrogen atom, a C1-6 alkyl group, or the like; and n represents an integer of 0 or 1], a salt of the tetrahydroquinoline compound, or a solvate of the tetrahydroquinoline compound or the salt.
    本文披露了一种具有促进EPO产生活性和/或增强血红蛋白表达活性的低分子化合物。具体披露了一种EPO产生促进剂和/或血红蛋白表达增强剂,包括1-酰基-4-(苯氧基、苄氧基或苯基氨基)-1,2,3,4-四氢喹啉衍生物,更具体地说是由通式(1)表示的四氢喹啉化合物;[其中R1、R2、R2'、R3和R3'独立地表示氢原子、C1-6烷基或类似物;R4、R5、R6、R7、R8、R9和R10独立地表示氢原子、卤素原子、C1-6烷基或类似物;A表示N-R11或氧原子;R11表示氢原子、C1-6烷基或类似物;n表示0或1的整数],四氢喹啉化合物的盐,或四氢喹啉化合物或其盐的溶剂结晶体。
  • 3-phenoxy-4-pyridazinol derivatives and herbicide composition containing the same
    申请人:Tsukamoto Yoshihisa
    公开号:US20050037925A1
    公开(公告)日:2005-02-17
    A compound represented by the formula: [wherein R 1 represents a hydrogen atom, a halogen, atom, alkyl group, etc., R 2 represents a hydrogen atom, a halogen atom, alkyl group, etc., R 3 , R 4 , R 5 , R 6 and R 7 each independently represent a hydrogen atom, a halogen atom, a substitutable alkyl group, a substitutable alkenyl group, alkynyl group, a substituteable cycloalkyl group, etc., or R 3 , R 4 , R 5 , R 6 and R 7 may form a ring which may be substituted, which is formed by the adjacent two of them with carbon atoms to which the respective substituents are bonded, m and n each independently represent 0 or 1.] a salt thereof, an ester derivative thereof and an agricultural chemical containing the same as an effective ingredient, and a herbicidal composition containing the compound and a second herbicidally active compound as effective ingredients.
    一种化合物由以下式子表示:[其中R1代表氢原子,卤素原子,烷基团等,R2代表氢原子,卤素原子,烷基团等,R3,R4,R5,R6和R7各自独立地代表氢原子,卤素原子,可替换的烷基团,可替换的烯基团,炔基团,可替换的环烷基团等,或R3,R4,R5,R6和R7可以形成一个环,该环可以被取代,该环由相邻的两个碳原子形成,这些碳原子与相应的取代基团相连,m和n各自独立地代表0或1。]其盐,酯衍生物及含有该化合物为有效成分的农药,以及含有该化合物和第二种草甘膦活性化合物为有效成分的除草剂组合物。
  • Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof
    申请人:Kuramochi Hiroshi
    公开号:US20070129383A1
    公开(公告)日:2007-06-07
    Disclosed is a [1,2,4]triazolo[1,5-a]pyrimidine derivative represented by the general formula (I) below or a pharmaceutically acceptable salt thereof. Also disclosed is a medicine containing such a derivative or a salt thereof as an active constituent. In the formula, Ar represents a phenyl group which may have a substituent or a 5- or 6-membered aromatic heterocyclic ring which contains one heteroatom and may have a substituent, and R represents a (C 1 -C 6 ) alkyl group which may be substituted or the like.
    本发明涉及一种由下述通式(I)表示的[1,2,4]三唑并[1,5-a]嘧啶衍生物或其药学上可接受的盐。还公开了一种包含该衍生物或其盐作为活性成分的药物。在该式中,Ar代表苯基,该苯基可以具有取代基或含有一个杂原子的5-或6-成员芳香杂环,该芳香杂环可以具有取代基;R代表(C1-C6)烷基,该烷基可以被取代或类似。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物